Jesse Anderson Corley Purchases 1,443 Shares of RxSight, Inc. (NASDAQ:RXST) Stock

RxSight, Inc. (NASDAQ:RXST) Director Jesse Anderson Corley purchased 1,443 shares of the stock in a transaction dated Wednesday, January 15th. The stock was purchased at an average price of $31.18 per share, for a total transaction of $44,992.74. Following the completion of the acquisition, the director now directly owns 1,443 shares in the company, valued at approximately $44,992.74. This represents a ∞ increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website.

Jesse Anderson Corley also recently made the following trade(s):

• On Tuesday, November 12th, Jesse Anderson Corley acquired 11,111 shares of RxSight stock. The stock was acquired at an average cost of $45.37 per share, with a total value of $504,106.07.

RxSight Price Performance

NASDAQ:RXST traded down $0.79 during trading hours on Friday, reaching $30.39. The company had a trading volume of 627,464 shares, compared to its average volume of 782,669. The firm has a market cap of $1.22 billion, a PE ratio of -36.61 and a beta of 1.20. RxSight, Inc. has a 1-year low of $26.29 and a 1-year high of $66.54. The business’s 50 day moving average price is $39.32 and its 200-day moving average price is $46.95.

Analyst Ratings Changes

Several equities analysts have recently issued reports on RXST shares. Wells Fargo & Company cut their price objective on shares of RxSight from $42.00 to $40.00 and set an “equal weight” rating on the stock in a report on Monday. Needham & Company LLC restated a “buy” rating and set a $66.00 price target on shares of RxSight in a research note on Monday. Stifel Nicolaus lowered their price objective on shares of RxSight from $40.00 to $35.00 and set a “hold” rating for the company in a research note on Monday. Jefferies Financial Group began coverage on RxSight in a research note on Tuesday, October 29th. They issued a “buy” rating and a $72.00 target price for the company. Finally, UBS Group started coverage on RxSight in a report on Friday, December 6th. They issued a “buy” rating and a $52.00 price objective on the stock. Two analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to MarketBeat, RxSight has a consensus rating of “Moderate Buy” and an average target price of $58.13.

Institutional Trading of RxSight

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Geode Capital Management LLC raised its holdings in RxSight by 17.7% in the 3rd quarter. Geode Capital Management LLC now owns 817,117 shares of the company’s stock worth $40,398,000 after purchasing an additional 122,775 shares during the period. Victory Capital Management Inc. raised its stake in shares of RxSight by 21.0% during the 3rd quarter. Victory Capital Management Inc. now owns 259,864 shares of the company’s stock worth $12,845,000 after buying an additional 45,161 shares during the period. Algert Global LLC purchased a new position in shares of RxSight during the 2nd quarter valued at approximately $2,488,000. Baillie Gifford & Co. increased its holdings in RxSight by 17.0% in the 3rd quarter. Baillie Gifford & Co. now owns 419,004 shares of the company’s stock worth $20,711,000 after acquiring an additional 60,789 shares in the last quarter. Finally, Barclays PLC raised its position in shares of RxSight by 389.8% during the 3rd quarter. Barclays PLC now owns 58,786 shares of the company’s stock worth $2,906,000 after purchasing an additional 46,783 shares during the last quarter. Institutional investors and hedge funds own 78.78% of the company’s stock.

About RxSight

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.